Online inquiry

IVTScrip™ mRNA-Anti-IL3RA, DT-IL-3(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ6840MR)

This product GTTS-WQ6840MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets IL3RA gene. The antibody can be applied in Chronic lymphocytic leukemia (CLL) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_001267713.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3563
UniProt ID P26951
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL3RA, DT-IL-3(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ6840MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ11727MR IVTScrip™ mRNA-Anti-IGF1R, MK-0646(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA MK-0646
GTTS-WQ125MR IVTScrip™ mRNA-Anti-EGFR, 11F8(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA 11F8
GTTS-WQ12800MR IVTScrip™ mRNA-Anti-NOTCH2&NOTCH3, OMP-59R5(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA OMP-59R5
GTTS-WQ2902MR IVTScrip™ mRNA-Anti-IL17RA, AMG827(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA AMG827
GTTS-WQ14935MR IVTScrip™ mRNA-Anti-stx2 A-subunit, Shigamabs®(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA Shigamabs®
GTTS-WQ8495MR IVTScrip™ mRNA-Anti-ITGAL, hu1124(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA hu1124
GTTS-WQ10721MR IVTScrip™ mRNA-Anti-FCGRT, M-281(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA M-281
GTTS-WQ5857MR IVTScrip™ mRNA-Anti-CD40, CHIR-12,12(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA CHIR-12,12
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW